Shalby, a prominent healthcare provider, has recently announced its impressive Q4 results for the year 2024. The company reported a substantial increase in revenue by 22.74% year-over-year, reaching a new high. This growth in revenue showcases Shalby’s strong performance and operational efficiency.
Moreover, the company’s profit also saw a healthy growth of 19.26% compared to the same quarter last year. Despite a slight decrease in profit compared to the previous quarter, Shalby managed to increase its revenue by 13.05%, indicating a positive trend in the company’s financials.
Shalby’s Selling, general & administrative expenses rose by 5.76% quarter-over-quarter but decreased by 4.19% year-over-year, demonstrating effective cost management strategies. The operating income witnessed a significant increase of 81.17% year-over-year, offsetting the decrease from the previous quarter, indicating better operational performance.
The company reported an Earnings Per Share (EPS) of ₹1.49 for Q4, marking a 14.58% increase year-over-year, reflecting positively on the company’s profitability. Despite mixed stock performance results, Shalby continues to be a prominent player in the healthcare sector with a market capitalization of ₹2897.41 Cr.
Analysts covering Shalby have provided positive ratings, with a consensus recommendation of Strong Buy, indicating confidence in the company’s performance. With such strong financial results and market confidence, Shalby is poised for continued success in the healthcare industry. Stay updated on quarterly results with Shalby’s results calendar.